Compare KVYO & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KVYO | PTCT |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | 2368 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 6.0B |
| IPO Year | 2023 | 2006 |
| Metric | KVYO | PTCT |
|---|---|---|
| Price | $18.61 | $69.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 17 |
| Target Price | $34.48 | ★ $80.65 |
| AVG Volume (30 Days) | ★ 5.6M | 735.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.29 | ★ 264.48 |
| EPS | N/A | ★ 0.90 |
| Revenue | ★ $1,234,019,000.00 | $264,734,000.00 |
| Revenue This Year | $24.47 | N/A |
| Revenue Next Year | $19.66 | $17.70 |
| P/E Ratio | $657.67 | ★ $77.00 |
| Revenue Growth | 31.63 | ★ 36.19 |
| 52 Week Low | $12.53 | $57.74 |
| 52 Week High | $36.23 | $90.87 |
| Indicator | KVYO | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 45.92 |
| Support Level | $15.67 | $67.57 |
| Resistance Level | $21.74 | $73.86 |
| Average True Range (ATR) | 0.92 | 2.00 |
| MACD | 0.15 | 0.17 |
| Stochastic Oscillator | 76.02 | 54.08 |
Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.